Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
20 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Crescendo Biologics Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Crescendo Biologics Limited - Product Pipeline Review - 2014', provides an overview of the Crescendo Biologics Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Crescendo Biologics Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Crescendo Biologics Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Crescendo Biologics Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Crescendo Biologics Limited's pipeline products Reasons to buy - Evaluate Crescendo Biologics Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Crescendo Biologics Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Crescendo Biologics Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Crescendo Biologics Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Crescendo Biologics Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Crescendo Biologics Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Crescendo Biologics Limited Snapshot 4 Crescendo Biologics Limited Overview 4 Key Information 4 Key Facts 4 Crescendo Biologics Limited - Research and Development Overview 5 Key Therapeutic Areas 5 Crescendo Biologics Limited - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Crescendo Biologics Limited - Pipeline Products Glance 9 Crescendo Biologics Limited - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 Discovery Products/Combination Treatment Modalities 10 Crescendo Biologics Limited - Drug Profiles 11 CB-001 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 Monoclonal Antibodies To Antagonize CD3 for Cancer 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 Monoclonal Antibody Conjugates for Cancer 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Crescendo Biologics Limited - Pipeline Analysis 14 Crescendo Biologics Limited - Pipeline Products by Target 14 Crescendo Biologics Limited - Pipeline Products by Route of Administration 15 Crescendo Biologics Limited - Pipeline Products by Molecule Type 16 Crescendo Biologics Limited - Pipeline Products by Mechanism of Action 17 Crescendo Biologics Limited - Locations And Subsidiaries 18 Head Office 18 Appendix 19 Methodology 19 Coverage 19 Secondary Research 19 Primary Research 19 Expert Panel Validation 19 Contact Us 20 Disclaimer 20
List of Tables Crescendo Biologics Limited, Key Information 4 Crescendo Biologics Limited, Key Facts 4 Crescendo Biologics Limited - Pipeline by Indication, 2014 6 Crescendo Biologics Limited - Pipeline by Stage of Development, 2014 7 Crescendo Biologics Limited - Monotherapy Products in Pipeline, 2014 8 Crescendo Biologics Limited - Preclinical, 2014 9 Crescendo Biologics Limited - Discovery, 2014 10 Crescendo Biologics Limited - Pipeline by Target, 2014 14 Crescendo Biologics Limited - Pipeline by Route of Administration, 2014 15 Crescendo Biologics Limited - Pipeline by Molecule Type, 2014 16 Crescendo Biologics Limited - Pipeline Products by Mechanism of Action, 2014 17
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.